The effects of antiarrhythmic drugs on the signal-averaged electrocardiogram in patients with malignant ventricular arrhythmias

Clinical significance of variability of ventricular late potentials detected before discharge in patients after myocardial infarction

BACKGROUND

Signal-averaged electrocardiography (SAECG) in patients after myocardial infarction (MI) is widely used to identify patients at risk for ventricular tachycardia (VT) and sudden cardiac death (SCD). It is believed that ventricular late potentials when detected after day 5 after MI are relatively stable and carry the most significant relation to subsequent arrhythmic events. This study sought to determine if ventricular late potentials in patients after MI exhibit variability when recordings were made 10 to 12 hours apart on day 7 and to assess the clinical significance of this variability.

METHODS AND RESULTS

SAECG was recorded in 261 patients on the 7th day after MI at 7 to 10 AM (morning) and 6 to 8 PM (evening). Forty of these patients also had recordings 30 to 40 minutes apart to determine the 95% confidence interval of variability of each parameter of SAECG. The data were analyzed with the criteria of the American College of Cardiology policy statement. A prospective analysis for the clinical end points of VT and SCD was carried out for a period of 1 year. We identified 3 groups of patients. Group 1 (54, 20.7%) had consistently positive SAECG by at least 2 abnormal parameters in both morning and evening. Group 2 (37, 14.2%) had positive SAECG at 1 time only, either morning or evening. Group 3 (170, 65.1%) had negative SAECG on both occasions. Diabetes mellitus was an independent predictor of the variability of late potentials (P <.0001). A prospective analysis for the clinical end points of VT and SCD showed that the event rate was significantly higher in group 1 than in group 2 (P <.019).

CONCLUSIONS

To improve the positive predictive value of SAECG in patients after MI, we advise that all positive tests be repeated 10 to 12 hours later, especially in patients with diabetes mellitus. Such testing will identify patients with consistently positive SAECG who appear to be at the highest risk for VT and SCD.

Circadian variability of late potential analysis in Holter electrocardiograms

Appearance of ventricular tachycardia, ventricular fibrillation, and sudden cardiac death has diurnal variations. We retrospectively studied, using digital Holter electrocardiogram, whether a time course in the appearance of late potentials may be associated with malignant ventricular arrhythmias. The 24-hour recordings in 200 patients after myocardial infarction (50 patients with documented, sustained, monomorphic and reproducibly inducible ventricular tachycardia (< 270/min) (group I), 50 patients resuscitated from ventricular fibrillation (group II), and 100 patients without ventricular arrhythmias (group III) were divided into 24 segments, 60 minutes each. Late potential analysis was performed using the Simson method in the time domain in each segment and compared to a conventional short-term registration. Late potential analysis in conventional short-term recordings during arbitrarily chosen daytimes revealed late potentials in 80% of patients in group I, 38% of patients in group II, and in 16% of patients without ventricular arrhythmias. In at least one 60-minute segment late potentials were found in group I in 92%, in group II in 88% (P < 0.05 vs conventional analysis), and in group III in 19%. Interestingly, in patients with a history of ventricular fibrillation late potentials appeared significantly more often during morning hours (6-12 AM: 82% vs 26% at 12 AM-6 PM, 30% at 6 PM-12 PM, and 42% at 12 PM-6 AM, P < 0.05), especially during phases with heart rate accelerations. Late potential analysis for risk stratification in conventional short-term recordings is feasible for patients prone to ventricular tachycardia, but patients prone to ventricular fibrillation would be more effectively stratified using 24-hour registrations with detection of circadian variations of late potential appearance.

Risk stratification after myocardial infarction using signal-averaged electrocardiographic criteria adjusted for sex, age, and myocardial infarction location

BACKGROUND

The objectives were to investigate the factors influencing signal-averaged ECGs (SAECGs) recorded in patients after myocardial infarction (MI) and to develop criteria for predicting arrhythmic events (AEs) that account for these factors.

METHODS AND RESULTS

SAECGs were recorded 5 to 15 days after MI in 2461 patients without bundle-branch block. The duration (QRSd), terminal potential (VRMS), and terminal duration (LAS) of the filtered QRS were measured. During follow-up (17 +/- 8 months), AEs (arrhythmic death; ventricular tachycardia, VT; ventricular fibrillation, VF) occurred in 80 patients (3.3%). Receiver operating characteristic curves showed that QRSd discriminated patients with all types of AEs, but VRMS and LAS discriminated only VT patients; QRSd minus LAS also discriminated AE patients. Sex, age, and MI location significantly affected the SAECG; survivors without VT or VF were divided into subgroups (2 sex x 4 age x 2 MI), and QRSd values exceeding the 70th percentile in each subgroup predicted AEs with a sensitivity of 65.4%. An unadjusted QRSd criterion showed the same overall sensitivity and specificity but with less uniform values for each subgroup. A Cox model was constructed by use of multiple prognostic indicators, and in rank order, QRSd, previous MI, and Killip class were predictive of AEs.

CONCLUSIONS

SAECG adjustments for sex, age, and MI location did not improve sensitivity and specificity but produced a more uniform predictive performance. The proposed criteria are based only on QRSd, because late potentials (VRMS and LAS) did not discriminate patients with sudden death. Duration of high-level activity during QRS (QRSd-LAS) can predict AEs, suggesting that the arrhythmogenic substate involves a large mass of myocardium.

The effects of intravenous mexiletine on spectra of the signal-averaged ECG

This study examined the effects of intravenous mexiletine on the time-domain and spectrotemporal signal-averaged ECG (SAECG). SAECGs were recorded in 60 postmyocardial infarction (MI) patients with more than 100 premature ventricular beats per hour, before and after a constant infusion of mexiletine, 7 mg/kg, given over 1 hour. Spectrotemporal analysis was done on a fixed analyzed signal duration of QRS complex and ST segment of X, Y, and Z leads using a temporal window of rectangular type, measuring the signal content between 10-120 Hz. Intravenous mexiletine produced no significant change in the mean values of any of the time-domain variables. However, mexiletine either increased or decreased the power density spectrum (PDS) and PDS ratio (40-120 Hz/25-120 Hz) of the SAECG, and in rare cases only did it not alter the spectra of the SAECG. When PDS ratio in lead Z decreased after mexiletine, it was usually higher at baseline in comparison with that when the PDS ratio increased, or vice versa. When the treatment with mexiletine was effective, PDS increased in comparison with that when the drug was ineffective, or vice versa. Not all ranges (10-120 Hz) of spectra of the SAECG, but only certain frequency bands (25-40 Hz in lead Z, P = 0.0253; 40-55 Hz in lead Y, P = 0.0096; 55-70 Hz in X lead, P = 0.0018; and in lead Z, P = 0.0002; 70-85 Hz in lead X, P = 0.0025; and in lead Z, P = 0.0075, 85-100 Hz in lead X, P = 0.0033) were associated with mexiletine efficacy.(ABSTRACT TRUNCATED AT 250 WORDS)

Signal-averaged ECG in prediction of the short-term suppression of ventricular premature beats by Mexiletine

We analyzed whether baseline parameters of time-domain and spectrotemporal analysis of a signal-averaged ECG or their changes during Mexiletine therapy can predict the antiarrhythmic efficacy of the drug. On 60 post-MI patients with > 100 ventricular premature beats per hour, signal-averaged ECGs were recorded before and after a constant infusion of Mexiletine (7 mg/kg) for 1 h and again after 4 days of oral Mexiletine therapy (Mexiletine SR, 360 mg twice daily). Spectrotemporal analysis was performed on a fixed analyzed signal duration of QRS-complex and ST-segment of X-, Y-, Z-leads using the temporal window of the rectangular type, measuring signals between 10-20 Hz. Intravenous and oral Mexiletine did not produce significant changes in mean values of any time-domain parameters. However, using informative variables of spectra of the signal-averaged ECG, we managed retrospectively to predict antiarrhythmic efficacy in 92% of the patients. Only certain frequency bands (from the range of the spectra at baseline, 10-120 Hz) were predictive for intravenous Mexiletine efficacy: 40-55 Hz in lead Y (P = 0.0116); 55-70 Hz in leads X and Z (P = 0.0063 and P = 0.0269, respectively); 70-85 Hz in lead Z, (P = 0.0227). When the treatment with intravenous Mexiletine was effective, the baseline power spectrum density was lower than when the drug was ineffective, and vice versa. Moreover, the efficacy of oral Mexiletine can be predicted by power density spectrum at baseline (10-25 Hz in lead Z, P = 0.0210; 70-85 Hz in lead Y, P = 0.0254) and by one of the possible (increased, decreased, unchanged) effects of intravenous Mexiletine on the spectra at frequency bands (70-85 Hz in lead X, P = 0.0432 and 40-120 Hz in lead Z, P = 0.0156). These results show the value of spectrotemporal signal-averaged ECG in selecting a subgroup of post-myocardial infarction patients that may benefit from Mexiletine therapy.

Variation in late potentials and the reproducibility of their measurement

The usefulness of a test depends on its reproducibility. This determines how closely the test result indicates the actual pathophysiologic state, how well it will predict that state in the future, and if interventions or further pathologic changes are reflected by the test. There is a variation in the parameters of the signal-averaged ECG, more so with spectral than with time domain measurements. These must be accounted for when estimating risk. If one presumes that risk is proportional to the extent of abnormality, then the variation in measurements simply means that only borderline cases can potentially be miscategorized. More important, the lack of reproducibility of measurements made from the signal-averaged ECG indicates that changes noted in an individual after an intervention, such as a surgical intervention, must be viewed with a jaundiced eye. Group changes are perhaps meaningful, and indicate a physiologic effect, but clinical decisions cannot be made unless the changes observed in an individual patient exceed the confidence limits of expected variation. There has been debate as to the usefulness of measurements made from the signal-averaged ECG in predicting antiarrhythmic drug effects (the effect of drugs is discussed elsewhere in this symposium). Here an analogy must be made to the suppression of asymptomatic ventricular ectopy. First, we cannot make a statement that there has been a drug effect unless the parameter measured changes beyond the confidence limits of normal variation or reproducibility. Second, we cannot translate a change in a measurement into a change in risk for arrhythmic events without subjecting that hypothesized relationship to a long-term placebo-controlled clinical trial, albeit acute electrophysiologic trials correlating changes in the signal-averaged ECG to ventricular tachycardia induction provide some insight. And perhaps the relationship must be tested independently for each drug assessed. In the same regard, there is much excitement about the benefits of thrombolytic therapy, but when diagnosing benefit to the individual patient we have to remember the lack of reproducibility of the measurements and also keep in mind that an improved signal-averaged ECG cannot be translated into an improved prognosis without long-term controlled studies. In summarizing the variation and reproducibility of measurements made from the signal-averaged ECG we avoided providing more than a sense of the extent of variation expected because precise confidence intervals depend on the particular techniques used to make the measurements.(ABSTRACT TRUNCATED AT 400 WORDS)